Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 September 2021 | Story Dr Nitha Ramnath
Prof Bonang Mohale.


The executive management of the University of the Free State (UFS) and the university community extend heartfelt congratulations to Prof Bonang Mohale on his appointment as President of Business Unity South Africa (BUSA). 

“Prof Mohale’s extensive expertise and experience in leadership roles, contributions to the growth of many multinational companies, and involvement in education and the business sector, will undoubtedly strengthen the ties between various sectors and civil society, and further contribute to the stabilisation and growth of South Africa,” said Prof Francis Petersen, UFS Rector and Vice-Chancellor, in his congratulatory letter to Prof Mohale. 

BUSA’s role in influencing policy and legislative development for inclusive growth and employment, and in building an enabling environment for the creation of a vibrant, diverse, and globally competitive economy that harnesses the economic and human potential in South Africa, is well documented. This potential resides in our higher education institutions in the form of our students, future graduates, and graduates who are the building blocks for the development of South Africa. 

At a time when our country is facing a social and economic crisis, we are confident that BUSA will consider the perspectives across sectors with a view to creating partnerships, collaboration, and co-creation and further play an integral role in our higher education institutions for the benefit of our students. 

“Prof Mohale’s support to the UFS is appreciated, especially his role as Chancellor and his contribution towards our Thought-Leader and Global Citizen programmes, through which important national and global issues are addressed.
 
We wish Prof Mohale every success in his endeavours, particularly as President of BUSA,” said Prof Petersen.

News Archive

Nano research at the UFS opens door to smart drugs
2011-06-27

 

Prof. Lodewyk Kock, outstanding professor in our Department of Microbial, Biochemical and Food Biotechnology

Novel antifungal, anticancer and anti-malaria drugs that have been identified in the research of Prof. Lodewyk Kock, outstanding professor in the Department of Microbial, Biochemical and Food Biotechnology at our university, will be disclosed later this year at major international conferences in Asia, Europe and the USA. Prof. Kock will be the keynote speaker at these conferences. 

His presentations will be based on the department’s discovery of yeast assays linked to a new nanotechnology for medicine. The assays were recently discovered by his group and can be applied in the development of novel antifungal, anticancer and anti-malaria drugs.
 
Prof. Kock’s focused research at the university, which now also includes his novel nanotechnology for Biology, began in 1982 in collaboration with Prof. Pieter van Wyk (Centre for Microscopy). He recently collaborated with Prof. Hendrik Swart (Department of Physics).
 
Prof. Kock says the development of novel anti-malaria drugs in particular is getting attention across the world due to the high rates of morbidity and mortality caused by the disease worldwide. Approximately 225 million people are infected annually and about a million (many in Africa) die each year. “Many potential smart drugs have been identified with this research and should now be tested further,” says Kock.
  
These new drugs will be disclosed during Prof. Kock’s keynote addresses at the International Conference and Exhibition on Pharmaceutical Regulatory Affairs in Baltimore, USA, from 6 to 7 September 2011, the Medichem 2011 in Beijing, China from 9 to 11 August 2011 and the XVI Congress of European Mycologists in Greece, from 19 to 23 September 2011.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept